Pulsed Field Ablation for Post-Infarction Ventricular Tachycardia
NCT: NCT06891456 · RECRUITING
Brief Summary
ASCEND is a randomized controlled open-label pilot study evaluating the safety and effectiveness of pulsed field ablation (PFA) with the novel FARAPOINT catheter compared to the standard radiofrequency (RFA) ablation with ThermoCool ST/FlexAbility SE/ThermoCool ST SF/TactiFlex SE of ventricular tachycardia (VT) in the patients with ischemic cardiomyopathy and implantable cardioverter-defibrillator (ICD). The study hypothesis is that the PFA ablation is more efficient compared to the RFA technique but retains a comparable safety profile.
Frequently Asked Questions
What is Pulsed Field Ablation for Post-Infarction Ventricular Tachycardia?
Pulsed Field Ablation for Post-Infarction Ventricular Tachycardia is a clinical trial registered under NCT06891456. Current status: RECRUITING.
What is the status of NCT06891456?
The current status of NCT06891456 (Pulsed Field Ablation for Post-Infarction Ventricular Tachycardia) is: RECRUITING.
When did Pulsed Field Ablation for Post-Infarction Ventricular Tachycardia start?
Pulsed Field Ablation for Post-Infarction Ventricular Tachycardia started on 2025-06-16.
Related Devices
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.